IBDEI2W9 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,46163,2)
 ;;=^5138344
 ;;^UTILITY(U,$J,358.3,46164,0)
 ;;=H35.3230^^176^2300^24
 ;;^UTILITY(U,$J,358.3,46164,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46164,1,3,0)
 ;;=3^Exudative ARMD,Bilateral
 ;;^UTILITY(U,$J,358.3,46164,1,4,0)
 ;;=4^H35.3230
 ;;^UTILITY(U,$J,358.3,46164,2)
 ;;=^5138528
 ;;^UTILITY(U,$J,358.3,46165,0)
 ;;=H35.3130^^176^2300^37
 ;;^UTILITY(U,$J,358.3,46165,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46165,1,3,0)
 ;;=3^Nonexudative ARMD,Bilateral
 ;;^UTILITY(U,$J,358.3,46165,1,4,0)
 ;;=4^H35.3130
 ;;^UTILITY(U,$J,358.3,46165,2)
 ;;=^5138510
 ;;^UTILITY(U,$J,358.3,46166,0)
 ;;=Z13.5^^176^2300^52
 ;;^UTILITY(U,$J,358.3,46166,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46166,1,3,0)
 ;;=3^Screening for Eye and Ear Disorders
 ;;^UTILITY(U,$J,358.3,46166,1,4,0)
 ;;=4^Z13.5
 ;;^UTILITY(U,$J,358.3,46166,2)
 ;;=^5062706
 ;;^UTILITY(U,$J,358.3,46167,0)
 ;;=Z48.02^^176^2300^51
 ;;^UTILITY(U,$J,358.3,46167,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46167,1,3,0)
 ;;=3^Removal of Sutures
 ;;^UTILITY(U,$J,358.3,46167,1,4,0)
 ;;=4^Z48.02
 ;;^UTILITY(U,$J,358.3,46167,2)
 ;;=^5063035
 ;;^UTILITY(U,$J,358.3,46168,0)
 ;;=Z48.810^^176^2300^1
 ;;^UTILITY(U,$J,358.3,46168,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46168,1,3,0)
 ;;=3^Aftercare Following EYE Surgery
 ;;^UTILITY(U,$J,358.3,46168,1,4,0)
 ;;=4^Z48.810
 ;;^UTILITY(U,$J,358.3,46168,2)
 ;;=^5063047
 ;;^UTILITY(U,$J,358.3,46169,0)
 ;;=H35.3131^^176^2300^40
 ;;^UTILITY(U,$J,358.3,46169,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46169,1,3,0)
 ;;=3^Nonexudative Age-Related Macular Degn,Early Dry Stage,Bilateral
 ;;^UTILITY(U,$J,358.3,46169,1,4,0)
 ;;=4^H35.3131
 ;;^UTILITY(U,$J,358.3,46169,2)
 ;;=^5138511
 ;;^UTILITY(U,$J,358.3,46170,0)
 ;;=H35.3132^^176^2300^41
 ;;^UTILITY(U,$J,358.3,46170,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46170,1,3,0)
 ;;=3^Nonexudative Age-Related Macular Degn,Intermed Dry Stage,Bilateral
 ;;^UTILITY(U,$J,358.3,46170,1,4,0)
 ;;=4^H35.3132
 ;;^UTILITY(U,$J,358.3,46170,2)
 ;;=^5138512
 ;;^UTILITY(U,$J,358.3,46171,0)
 ;;=H02.889^^176^2300^35
 ;;^UTILITY(U,$J,358.3,46171,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46171,1,3,0)
 ;;=3^Meibomian Gland Dysfunction,Unspec
 ;;^UTILITY(U,$J,358.3,46171,1,4,0)
 ;;=4^H02.889
 ;;^UTILITY(U,$J,358.3,46171,2)
 ;;=^5157349
 ;;^UTILITY(U,$J,358.3,46172,0)
 ;;=Z96.1^^176^2300^46
 ;;^UTILITY(U,$J,358.3,46172,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46172,1,3,0)
 ;;=3^Presence of Intraocular Lens
 ;;^UTILITY(U,$J,358.3,46172,1,4,0)
 ;;=4^Z96.1
 ;;^UTILITY(U,$J,358.3,46172,2)
 ;;=^5063682
 ;;^UTILITY(U,$J,358.3,46173,0)
 ;;=H43.813^^176^2300^53
 ;;^UTILITY(U,$J,358.3,46173,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46173,1,3,0)
 ;;=3^Vitreous Degeneration,Bilateral
 ;;^UTILITY(U,$J,358.3,46173,1,4,0)
 ;;=4^H43.813
 ;;^UTILITY(U,$J,358.3,46173,2)
 ;;=^5005955
 ;;^UTILITY(U,$J,358.3,46174,0)
 ;;=H26.491^^176^2300^44
 ;;^UTILITY(U,$J,358.3,46174,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46174,1,3,0)
 ;;=3^PCO/Secondary Cataract,Right Eye
 ;;^UTILITY(U,$J,358.3,46174,1,4,0)
 ;;=4^H26.491
 ;;^UTILITY(U,$J,358.3,46174,2)
 ;;=^5005358
 ;;^UTILITY(U,$J,358.3,46175,0)
 ;;=H26.492^^176^2300^43
 ;;^UTILITY(U,$J,358.3,46175,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46175,1,3,0)
 ;;=3^PCO/Secondary Cataract,Left Eye
 ;;^UTILITY(U,$J,358.3,46175,1,4,0)
 ;;=4^H26.492
